Background. Cardiovascular diseases and chronic obstructive pulmonary disease (COPD) are both associated with abdominal aortic aneurysms (AAA). The aim of this study was therefore to analyse whether screening for AAA could be restricted to men with such diseases (high risk group). Methods. Before the date of randomisation of a population screening trial of 12,639 64e73-year-old males, all discharge diagnoses from the National Patient Registry concerning AAA-related diseases were merged with the screening results on attendance, AAA prevalence, and AAA-related mortality and overall mortality. Differences in proportions were compared by Chi square tests and differences in mortality by Cox regression analyses. Results. The attendance rate was 78.8% and 6.7% had an AAA in the high risk group compared to 75.8% attendance (P < 0.001) and 2.9% (P < 0.001) in the remaining population. Cumulatively, screening of only high risk men with would have required 72.9% (95% C.I.: 72.3e74.5%) fewer screening invitations, would have discovered 46.1% (95% C.I.: 38.9e 53.4%) of the AAA cases diagnosed and prevented 46.7% (95% C.I.: 28.3e65.7%) of the AAA-related deaths. However, screening decreased AAA-related mortality both among men with and without known COPD or cardiovascular diseases: mortality ratio: 0.22 (95% C.I.: 0.08e0.65), P ¼ 0.006, and 0.24 (95% C.I: 0.09e0.63, P ¼ 0.004, respectively. Conclusion. High-risk population screening would prevent less than half of AAA-related deaths. Therefore, restricting screening to such high-risk groups does not seem justified, but cost effectiveness analyses are needed to reach a firm conclusion.
Introduction
Abdominal aortic aneurysms (AAA) seldom cause symptoms before rupture. Ultrasonographic screening is safe, valid and cheap, so it seems to be an ideal method for AAA screening. 1 In 1987, a group of screening experts worked for the Council of Europe, evaluating the 1968 WHO screening criteria. 2 The criteria were expanded and new criteria were formulated. 3 One of the new criteria was that ''the screening test must be acceptable to the population to be screened''. They explained the meaning of this: ''this means not only a sufficient overall take-up, but also a sufficient take-up-rate for high risk''. 3 Hypertension, 4, 5 myocardial infarction (MI), 5 chronic obstructive pulmonary disease (COPD), 6 peripheral arterial occlusive disease, 7e9 angina pectoris, stroke or transient cerebral ischemia 10 are associated with AAA, and we have previously shown that patients with these other disorders attend population screening for AAA more frequently than those without such diseases. 10 However, sufficient attendance is not enough if the treatment is unacceptable for high-risk patients due to contraindications for surgery, or the adverse effects of the treatment outweigh the benefits for high risk patients. This could leave a large proportion of untreated men at high risk of aneurysm rupture, 11 and those offered operation would have increased risk of postoperative complications and deaths. 12 In all, the benefit of screening of a high risk group could be limited. On the other hand, the association between AAA and these diseases makes it possible that AAA screening could be restricted to such men.
The aims of this study were to perform a stratified analysis in a randomised population screening trial for AAA in men, with or without hospital diagnoses of COPD or cardiovascular disease, using the outcome measures of attendance, AAA prevalence, AAAspecific mortality and overall mortality.
Patients and Methods
In 1994 all men in Viborg County in Denmark born in 1921e1929 were randomised either to a to be offered an abdominal ultrasonographic scan at their regional hospital or to a control group without a scan. From 1995 to 1998, all men were recruited and randomised the year they turned 65 years. Controls were not informed about the trial. Randomisation produced 6306 controls and 6333 were invited for screening. 13 The invitation letter explained the trial and attendance was taken as consent of participation. The B-mode scans were carried out with a small portable Phillips SDR 1550 with a linear 4-mHz transducer and calliper light pen. An AAA was defined as an infrarenal aortic diameter of 30 mm or more. Patients with an AAA of 3e4.9 cm were offered follow-up examination, while patients with an AAA of 5 cm or more were referred to vascular evaluation for possible surgery. All previous discharge diagnoses recorded in the National Patient Registry concerning chronic obstructive pulmonary disease and cardiovascular diseases including hypertension were ascertained for all enrolled men up until the date of enrolment. This registry, established in 1977, records civil registration number, dates of discharge and up to 20 discharge diagnoses a.o. Diagnoses were classified according to the Danish version of the International Classification of Diseases (ICD), 8th revision, until the end of 1993, and according to the 10th revision hereafter. 6 Based on previous reports, 4e10 six groups were defined as having a high risk of AAA, hypertension, MI, COPD, other ischaemic heart disease MI, peripheral occlusive arterial disease affecting the lower limb, and stroke or transient ischemic attack (Table 1) . If a man was classified into one or more of these groups, he was considered as being at high risk for having an AAA (high risk group). A similar procedure was followed for hospital discharge diagnoses after the date of randomisation until 31 Dec. 2001.
Deaths were identified in the national Office of Civil Registration and causes of deaths were identified in the national Registry of Causes of Death 14 from the date of randomisation to 31 Dec. 2001 and potential AAA-related deaths were identified. The hospital and autopsy records of deaths coded as I71.3 (ruptured AAA) or I71.4 (unruptured AAA) as primary or participating cause of death were reviewed by two vascular surgeons, as described previously. 13 Differences in proportions were tested by Chi square tests. Hazards were used to estimate the AAAspecific mortality ratio by Cox regression analysis.
The proportional hazards assumption was evaluated graphically. Analyses were performed using SPSS 12.0, Stata 8.0 and PEPI. The survival analyses were calculated on the basis of ''intention to screen'' as from the date of randomisation to death or 31 Dec.
2001.
The trial was approved by the local scientific ethics committee and reported to the Danish Registry Board.
Results
Among the 6333 men randomized to screening, 4852 attended (76.6%), of whom 4816 had aortas visible on ultrasonography. Among these, 191 had an AAA (4.0%) ( Table 2) .
COPD and other cardiovascular disorders in the control group were associated with increased risk of AAA-related death with a mortality ratio of 2.70 (95% C.I.: 1.44e5.07), P ¼ 0.002.
The high-risk group
In all, 3355 (27.5% (95% C.I.: 25.8e27.3%)) had had a previous hospital discharge diagnosis of one or more relevant co-morbidities before randomisation. Screening only such high risk men would therefore require 1681 invitations instead of 6333, corresponding to 72.9% (95% C.I.: 72.3e74.5%) fewer screening invitations (Tables 2 and 3 ).
The mean age and follow-up period are shown in Table 3 . There were no significant differences between A Third column shows the difference in proportion of attenders to screening in the specific high-risk group using those not included in the specific high-risk group as reference. B Sixth column shows the difference in proportion of having an AAA for men in the specific high-risk group using those not included in the specific high-risk group as reference.
1 Acute myocardial infarction. 2 Chronic obstructive pulmonary disease. 3 Ischemic heart disease. 4 Peripheral occlusive arterial disease. 5 Transient ischemic attack. Fig. 1 . Flow-chart concerning screening for abdominal aortic aneurysm classified according to pre-existing hospital admissions due to AAA-related disease (high risk) or not (low risk).
the invited group and the control group in terms of age and follow-up.
The screening attendance rate in high risk subjects was 78.8%. Among these, 88 (6.7%, 95% C.I.: 5.4e 8.1%) had an AAA, compared with 191 in the total population screening, corresponding to 46% (95% C.I.: 39e53%) of all the AAAs diagnosed.
Among those with a previous MI, 82.5% attended and 8.9% (95% C.I.: 6.6e11.7%) had an AAA (Table 3) .
In all, 1217 died in the high-risk group. Among these, 22 died due to AAA: 4 in the invited group and 18 in the control group (hazard ratio: 0.22 (95% C.I.: 0.08e0.65), P ¼ 0.006, Figs. 1 and 2) . ''Overall, 39 died of AAA in the control group and 9 in the invited group (Table 1) . Consequently, high risk screening alone would have prevented 14 of the prevented 30 AAA related deaths observed in the population screening trial, corresponding to 46.7% (95% C.I.: 28.3e65.7%) of the AAA-related deaths prevented in the randomised mass screening trial.
The low-risk group
In all, 9284 (73.5% (95% C.I.: 72.7e74.2%)) had no prerandomisation discharge diagnosis of one or more AAA-related diseases, mean age and follow-up are given in Table 3 , and there were no differences between the invited group and the control group in terms.
The attendance and AAA prevalence rates were significantly lower than the rates seen in the high-risk group: 75.8% attended (P < 0.001) and 103 (2.9%, 95% C.I.: 2.4e3.5%) had an AAA (P < 0.001). The difference in the proportion of attendance and the prevalence of AAA between the high-and the low-risk group was 3.0% (95% C.I.: 0.7e6.1%) and 3.8% (95% C.I.: 2.3e5.3%), respectively. Overall, 1611 subjects died, 26 of AAA-related causes: 5 from the invited group and 21 form the control group (hazard ratio: 0.24 (95% C.I: 0.09e0.63, P ¼ 0.004, Fig. 3 ). Low-risk screening would have prevented 16 of the 30 prevented AAA deaths in the whole mass screening trial, corresponding to 53.3% (95% C.I.: 34.3e71.7%).
Discussion
Screening significantly decreased AAA-related mortality equally in men with and without COPD and/or other cardiovascular diseases. The pattern, reported previously, that men at high risk for having an AAA attended screening more frequently than men at lower risk was confirmed after additional recruitment of 65-year-old men in the 4 years after the initial study. 10 Limiting screening to high risk men (with COPD and/or other cardiovascular diseases) would have reduced the number screened individuals by 73%, but at a cost of missing 52% of the AAAs in the overall population. The number of outcomes almost doubled the number in the high-risk group during the observation period. The target group was men aged 64e73. If permanent screening was to be introduced, the target group would probably only include 65-year-old men, and the proportion of men at high risk would therefore be much lower.
For some diagnoses, e.g. hypertension, 15 Danish studies have reported considerable misclassification bias with only 40e60% of cases registered although other cardiovascular discharge diagnoses such as MI and COPD have shown a positive predictive value both reaching 90%. 16, 17 Errors in co-morbidity reporting and lack of information about smoking habits biases the results towards the null hypothesis, but it also allows quick identification of men at high risk. It would probably have been possible to identify more high-risk men and consequently to have included more of the AAA diagnosed in the high-risk group if we had searched the written hospital and GP records. However, it would hardly have been worth the effort because the total time consumption per scan in massscreening was less than 10 minutes including invitation, information, scanning and registration. 18 The direct costs of a screening scan were £7.48. 18 Based upon these costs and the AAA prevalences observed in the high risk and the remaining population groups, we estimate the detection costs at approx. £115 for diagnosing an AAA in the high-risk group and approx. £260 in the low-risk group. This is a small difference, but direct scanning costs account for less than 10% of the total screening costs 17 and that the co-morbidities of the high risk group are likely to be associated with increased postoperative complications and mortality and reduced long-term survival. The long-term costs per saved living year therefore may be increased in the high-risk groups compared with the low-risk group, but the best proof of this would be an advanced cost effectiveness analysis.
